The clinical effectiveness agency for England and Wales said that it would not recommend imatinib as a post-surgical treatment for people who have had a gastrointestinal stromal tumor, or GIST, removed and are at risk of the cancer recurring. The National Institute for Health and Clinical Excellence cited imatinib's expense, at an estimated £19,500 per patient per year, and a lack of complete clinical evidence as factors in its decision, which is not yet final. Imatinib (Glivec, Novartis Pharmaceuticals...